- RecruitingPHASE3
NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
This study is looking into a new medication called NBI-1065845 for people with depression who haven't fully responded to their current antidepressants. It will compare the new medication to a dummy pill (placebo) to see if it helps improve symptoms when added to existing treatment.
For: Major Depressive DisorderUnited States · Belgium · Canada - RecruitingPHASE3
Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
This study is looking at a new medicine called NBI-1065845 for people with depression. It's for those already taking antidepressants but still struggling. The main goal is to check its long-term safety and if people can take it alongside their usual treatment.
For: Major Depressive DisorderUnited States · Belgium · Bulgaria